Navigation Links
Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
Date:2/1/2012

Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 11:15 a.m. Eastern Time on February 1, 2012 through 12:00 a.m. Eastern Time on March 1,  2012 by dialing:

Domestic:
(800) 585-8367
International:
(404) 537-3406
Conference ID:
48497482

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "esti
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 EnteroMedics Inc. (NASDAQ: ... technology to treat obesity, metabolic diseases and other gastrointestinal ... call on Thursday, August 6, 2015, at 11:00 AM ... quarter ended June 30, 2015, and to provide an ... Therapy, delivered via the Maestro® System. Conference ...
(Date:7/30/2015)... , July 30, 2015 ... "The Group") the regenerative medical devices company, announces ... the post-acute wound care market as Tissue Regenix ... DermaPure® under Medicare administrator, First Coast Service Options ... Florida , Puerto Rico ...
(Date:7/30/2015)... 2015 ReportsnReports.com adds ... tumor biomarker tests, imaging, endoscopy and biopsy ... global industry by technology and application. ... Biomarker Tests, Imaging, Endoscopy and Biopsy) Report ... 9 companies and supported with 180 tables ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 2Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 4Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 5Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 6
... 24, 2011 Molecular Devices, Inc. and ChanTest Corporation, ... tools and solutions, have signed an agreement for Molecular ... and GPCR cell lines on a non-exclusive basis.  As ... ChanTest,s ion channel and GPCR cell lines and promote ...
... MELVILLE, N.Y., March 24, 2011 Henry Schein, Inc. ... health care products and services to office-based dental, medical ... the "Wholesalers:  Health Care" industry in Fortune ... the categories of Social Responsibility and Global Competitiveness.  The ...
Cached Medicine Technology:Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 2Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 3Henry Schein Ranks #1 in Its Industry for Social Responsibility as a Fortune 2011 World's Most Admired Company 2Henry Schein Ranks #1 in Its Industry for Social Responsibility as a Fortune 2011 World's Most Admired Company 3
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd Clay Today Online ... to fund the state’s large prison system, which has amassed largely enough throughout the ... incarceration. In light of President Obama’s recent reduction of non violent drug offender’s prison ...
(Date:7/30/2015)... ... , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers comprehensive ... as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with decades ... around the world. , “Like treatment of any other disease or condition, making the ...
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... ... , ... Author Dr. Raul Llanos seeks to empower readers to ... book, “ Consciously Healing our Webs of Health, Wellbeing, Success, and Abundance ” (published ... responsibility for ourselves, we can create better realities.” His book illustrates the possibilities of ...
(Date:7/30/2015)... ... , ... After a three year trial designed to study the efficiency and ... “bionic eye,” researchers have determined the trial to be a success, and are recommending ... affected by complete vision loss as a result of Retinitis pigmentosa. The results of ...
Breaking Medicine News(10 mins):Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... common cancer drug imatinib (Gleevec), researchers have eliminated morphine ... the effectiveness of chronic pain management in patients, according ... Cancer Center. Narcotics such as morphine are a ... the pain-relieving effects of these drugs can develop, requiring ...
... caused by an erosion of the protective caps on chromosomes, ... allows malignant cells to evade destruction and acquire more deadly ... journal Cell . In a strain of ... through this two-step process developed lethal cancer and 25 percent ...
... A Cedars-Sinai research scientist has been awarded two ... prestigious Research Project Grant from the National Institutes of ... Terrence Town, PhD, is studying drugs that ... amyloid plaques that build up in the brain and ...
... HealthDay Reporter , MONDAY, Feb. 20 (HealthDay News) -- Alcohol ... new national survey reveals. The online, anonymous poll indicated ... abuse or dependence: nearly 14 percent of male surgeons and ... 8 percent to 12 percent figure typically cited for alcohol ...
... Institute researchers will lead a symposium on relationships between ... autism in children during the American Association for the ... in Vancouver, Canada. The symposium, "Autism: Genetic, Epigenetic ... Feb. 18. The researchers, both affiliated with the UC ...
... Alzheimer,s disease drugs now being tested in clinical trials ... Northwestern Medicine research. A study with mice suggests the ... to be miswired and interfering with their ability to ... the scientist whose original research led to the drug ...
Cached Medicine News:Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 3Health News:Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 3Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 4Health News:UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver 2Health News:Alzheimer's drugs may have adverse side effects 2
... The full color LCD ... familiar joystick controls, enable any ... make quick and accurate measurements.,Measurement ... the color screen, and results ...
... Patients who need punctal ... dry eye relief. They also ... be as comfortable and as ... why Alcon punctal plugs are ...
... to diagnostic images and reports, the powerful ... scaled to meet the needs of virtually ... Web PACS system allows clinicians, referring physicians, ... view images and information on-site or at ...
... SonoAce 9900 is a ... ultrasound system, with an ... DICOM compatible, designed for ... imaging, obstetrics, gynecology, perinatology, ...
Medicine Products: